Case-Based Roundtable Meetings Spotlight April 2, 2021

May 14, 2021

Pashna N. Munshi, MD, discussed the case of a 48-year-old male patient with acute graft-versus-host-disease.

May 12, 2021

Jaffer A. Ajani, MD led a discussion around biomarkers to consider when determining systemic therapy for patients with stage IV gastric adenocarcinoma.

May 12, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Michael A. Carducci, MD, reviewed the results of the CARD trial to support his recommendation of cabazitaxel for the treatment of a 75-year-old man with metastatic castration-resistant prostate cancer.

May 11, 2021

The DECISION and SELECT studies provide evidence of response to multikinase inhibitors after disease progression in patients with thyroid carcinoma.

May 10, 2021

Corey J. Langer, MD, led a peer discussion around novel targets for adjuvant non–small cell lung therapy.

May 10, 2021

The PROfound and TRITON2 clinical trials have demonstrated the benefit of the PARP inhibitors olaparib and rucaparib for the treatment of metastatic castration-resistant prostate cancer.

May 08, 2021

Helen Moon, MD, reviewed the data from the JAVELIN Bladder 100 trial, which support the use of avelumab as maintenance therapy for patients with metastatic bladder cancer.

May 07, 2021

Luis Raez, MD, Hdiscussed the case of a 59-year-old patient with RET-mutated lung cancer.

April 22, 2021

During a Targeted Oncology Case-Based Roundtable event, Joseph Mikhael, MD, discusses responses observed in transplant-eligible patients with multiple myeloma.

April 21, 2021

David Dingli, MD, PhD, discussed the case of a 51-year-old patients with transplant-eligible myeloma.

April 19, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Bryan McIver, MD, PhD, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer.

April 18, 2021

Matthew Smith, MD, PhD, discussed the new hormone therapies entering the treatment landscape for metastatic castration-resistant prostate cancer.

April 17, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Alexander Spira, MD, PhD, discusses when the use of durvalumab followed by chemoradiotherapy is appropriate for patients with unresectable stage III non–small cell lung cancer.